Total
0
Shares
Alcidion Group (ASX:ALC) - Group Managing Director, Kate Quirke
Group Managing Director, Kate Quirke
Source: Alcidion Group
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Alcidion Group (ALC) expands the use of its remote patient monitoring platform, Miya Precision, with the Sydney Local Health District (LHD)
  • The contract extension will generate around an additional $1.8 million in revenue over the next three years
  • Last year, the parties signed a 12 month contract with Sydney LHD to manage the care of COVID-19 patients in home isolation
  • Alongside this contract, Alcidion and Sydney LHD will work together to deploy the patient app, Miya Care
  • Alcidion is up 4.29 per cent and is trading at 36.5 cents per share at 1:45 pm AEDT

Alcidion Group (ALC) has expanded the use of its remote patient monitoring platform, Miya Precision, with the Sydney Local Health District (LHD).

The contract extension will generate an additional estimated $1.8 million in revenue over the next three years.

Last year, the parties signed a 12 month contract with Sydney LHD for Miya. The agreement was established to manage the care of COVID-19 patients in home isolation.

Miya provides RPA Virtual Hospital (rpavirtual) clinicians with a clinical monitoring dashboard that consolidates information to support remote patient care. The technology aims to reduce required hospitalisations, support an increase in the numbers of patients who can be treated and improve recovery outcomes.

Alongside this contract, Alcidion and Sydney LHD will work together to deploy the patient app, Miya Care.

Speaking on this announcement is Managing Director Kate Quirke.

“We are very excited to build on our initial implementation of Miya Precision with Sydney Local Health District through this project that highlights the flexibility and scalability of our platform as a key enabler of new and innovative models of care,” Ms Quirke said.

“We believe Alcidion can play a meaningful role in the development of virtual care across the hospital system in Australia and this partnership with Sydney Local Health District provides a strong validation of that.”

Alcidion was up 4.29 per cent, trading at 36.5 cents per share at 1:45 pm AEDT.

ALC by the numbers
More From The Market Herald
Rhythm Biosciences (ASX:RHY) - CEO, Glenn Gilbert

" Rhythm Biosciences (ASX:RHY) achieves CE Mark for ColoSTAT

Cancer diagnostic technology company Rhythm Biosciences (RHY) has achieved CE Mark certification for ColoSTAT.
EMVision Medical Devices (ASX:EMV) - CEO, Ron Weinberger

" EMVision Medical Devices (ASX:EMV) reports more strong results

Medical device maker EMVision (EMV) is spiking on the ASX today after releasing further results from a pilot clinical trial of its brain
ECS Botanics (ASX:ECS) - Managing Director and Founder, Alex Keach

" ECS Botanics’ (ASX:ECS) subsidiary buds $4.9m supply agreement

ECS Botanics’ (ECS) subsidiary has secured a $4.9 million agreement to supply resin to Australian cannabis company, Cannvalate.
Arovella Therapeutics (ASX:ALA) - CEO and Managing Director, Dr Michael Baker

" Arovella Therapeutics (ASX:ALA) receives $524,000 R&D tax refund

Arovella Therapeutics (ALA) has received a refund from the Australian Taxation Office (ATO) of just over $524,000 for the financial year.